# Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification

> **NCT02066662** · PHASE4 · COMPLETED · sponsor: **RWTH Aachen University** · enrollment: 192 (actual)

## Conditions studied

- Atrial Fibrillation or Pulmonary Embolism
- Need of Long Term Oral Anticoagulation Therapy (OAT)
- Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location

## Interventions

- **DRUG:** Rivaroxaban or Marcumar

## Key facts

- **NCT ID:** NCT02066662
- **Lead sponsor:** RWTH Aachen University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2020-03
- **Final completion:** 2020-03
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2020-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02066662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02066662, "Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02066662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*